Advanced Drug Delivery Systems for Biopharmaceuticals

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 4, Issue , 2008, Pages 1360-1391

  Hildebrand, Gesine E ^a   Harnisch, Stephan ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Co polymer; Conjugates; Microreservoir; Multilamellae vesicles; Physico chemically

Indexed keywords

EID: 84889974137     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch56     Document Type: Chapter

References (163)

1. Gloff CA, Benet LZ: Pharmacokinetics and protein therapeutics, Adv Drug Del Rev 1990, 4, 359-386.
2. Yamahara H, Lee VHL: Drug metabolism in the oral cavity, Adv Drug Del Rev 1993, 12, 25-40.
3. Caliceti P, Veronese FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates, Adv Drug Del Rev 2003, 55, 1261-1277.
4. Yamamoto A, Hayakawa E, Lee VHL: Insulin and proinsulin in mucosal homogenates of the albino rabbit: implications in peptide delivery from normal routes, Life Sci 1990, 47, 2465-2474.
5. Lehr CM: (1991) Bioadhesive Drug Delivery Systems for Oral Application. Ph.D. Thesis, Leiden University, Netherlands.
6. Bundgaard H, Moss J: Prodrug of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by TRH-specific serum enzymes, Pharm Res 1990, 7, 885-892.
7. Bocci V: Catabolism of therapeutic proteins and peptides with implications for drug delivery, Adv Drug Deliv Rev 1990, 4, 149-169.
8. Latham PW: Therapeutic peptides revisited, Nat Biotechnol 1999, 17, 755-757.
9. Opalinska JB, Gewirtz AM: Nucleic-acid therapeutics: Basic principles and recent applications, Nat Rev Drug Disc 2002, 1, 503-514.
10. Gewirtz AM, Stein CA, Glazer PM: Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996, 93, 3161-3163.
11. Roerdink FH, Regts J, Van Leeuwen B, Scherphof GL: Intrahepatic uptake and processing of intravenously injected small unilamellar vesicles in rats. Biochim Biophys Acta 1984, 770, 195-202.
12. Turner NC, Wright NA: The response to injury. In: McGee JOD, Isaacson PG, Wright NA (Eds.), Oxford Textbook of Pathology. 1992, pp. 351-390, Oxford University Press, Oxford, UK.
13. Moghimi SM, Hunter AC, Murray JC: Long-Circulating and Target-Specific Nanoparticles: Theory to Practice, Pharmacol Rev 2001, 53, 283-318.
14. Takakura Y, et al.: Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties, J Pharm Sci 1989, 78, 219-222.
15. Veronese FM, Harris JM: Introduction and overview of peptide and protein pegylation, Adv Drug Deliv Rev 2002, 54, 453-456.
16. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals, Nat Rev Drug Disc 2003, 2, 214-221.
17. Torchilin VP, et al: Peptide and protein drug delivery to and into tumors: challenges and solutions, DDT 2003, 8, 259-266.
18. Maeda H, et al.: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J Control Release 2001, 74, 47-61.
19. Davis FF: The origin of pegnology, Adv Drug Del Rev 2002, 54, 457-458.
20. Veronese FM, Harris JM (Eds.): Special issue: Peptide and protein PEGylation, Adv Drug Del Syst 2002, 54, 453-609.
21. Roberts MJ, Bentley MD, Harris JM: Chemistry for peptide and protein PEGylation, Adv Drug Deliv Rev 2002, 54, 459-476.
22. Duncan R: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates, Nat Rev Drug Disc 2003, 2, 347-360.
23. Levy Y, et al.: Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase, J Pediatr 1988, 113, 312-317.
24. Maeda H, Konno T. In: Maeda H, Edo K, Ishida N (Eds.), Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug. pp. 227-267, Springer, Berlin, 1997.
25. Graham ML: PEGASPARAGINASE: a review of clinical studies, Adv Drug Deliv Rev 2003, 55, 1293-1302.
26. Muss HB, Spell N, et al.: A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphoma, Invest New Drugs 1990, 8, 125-130.
27. Wang Y-S, et al.: Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications, Adv Drug Deliv Rev 54, 2002, 547-570.
28. Reddy KR, Modi MW, Pedder S: Use of peginterferon, α-2a (40KD) (Pegasys®) for the treatment of hepatitis C, Adv Drug Deliv Rev 2002,54, 571-586.
29. Mukherjee A, et al.: How to optimise pegvisomant treatment of acromegaly safely?, Endocrine Abstracts 2002, 4, OC8.
30. Kinstler O, et al.: Mono-N-terminal poly(ethylene glycol)-protein conjugates, Adv Drug Deliv Rev 2002, 54, 477-485.
31. Duncan R, Coatsworth JK, Burtles S: Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1), Hum Exp Toxicol 1998, 17, 93-104.
32. Gianasi E, et al.: HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation, J Drug Targeting 2002, 10, 549-556.
33. Meerum Terwogt JM, et al.: Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel, Anticancer Drugs 2001, 12, 315-323.
34. Schoemaker NE, et al.: A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin, Br J Cancer 2002, 87, 608-614.
35. Mu Y, et al.: Bioconjugation of laminin peptide YIGSR with poly(styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of B16-BL6 melanoma cells, Biochem Biophys Res Commun 1999, 255, 75-79.
36. Maeda H: SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy, Adv Drug Deliv Rev 2001, 46, 169-185.
37. Li C, Yu DF, Newman RA, Cabral F, Stephens LC, Hunter N, Milas L, Wallace S: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate, Cancer Res 1998, 58, 2404-2409.
38. Kudelka AP, Verschraegen CF, Loyer E, Wallace S, Gershenson DM, Hon J, Ho L, Garzone PD, Warner M, Bolton MG, Kavanagh JJ: Preliminary report of a phase I study of escalating dose PG-paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors, Proc Am Soc Clin Oncol 2002, 21, 2 Pt 2, Abs 2146.
39. Garzone PD, Mitchell P, Bolton MG, Nemunaitis J: Preliminary report of a phase I study of combination chemotherapy using CT-2103 and carboplatin in patients with solid tumors, Proc Am Soc Clin Oncol 2002, 21, 2 Pt 2, Abs 2161.
40. Sabbatini P, Brown J, Aghajanian C, Hensley ML, Pezzulli S, Flaherty C, Lovegren M, Funt S, Warner M, Mitchell P, Bolton MG, et al: A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer, Proc Am Soc Clin Oncol 2002, 21, 1 Pt 2, Abs 871.
41. Harper H, Marsland T, Mitchell P, Infortuno J, Bolton MG: Phase II study of first line chemotherapy using CT-2103 in patients with non-small cell lung cancer who are >70 years of age or who have PS=2, Proc Am Soc Clin Oncol 2002, 21, 2 Pt 2, Abs 2685.
42. Hreczuk-Hirst D, Chicco D, German L, Duncan R: Dextrins as potential carriers for drug targeting: Tailored rates of dextrin degradation by introduction of pendant groups, Int J Pharm 2001, 230, 57-66.
43. Tomlison R, Heller J, Duncan R, Brocchini S: Pendent chain functionalised polyacetals that display pH-dependent degradation: A platform for the development of novel polymer therapeutics, Macromolecules 2002, 35, 473-480.
44. Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R: Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer, Urology 2000, 55, 639-642.
45. Stevenson CL, Tan MM: Solution stability of salmon calcitonin at high concentration for delivery in an implantable system, J Peptide Res 2000, 55, 129-139.
46. Cleland JL, Daugherty A, Mrsny R: Emerging protein delivery methods, Curr Opin Biotechnol 2001, 12, 212-219.
47. Anderson JM, Langone JJ: Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Control Release 1999, 57, 107-113.
48. Bangham A, et al.: Diffusion of univalent ions across lamellae of swollen phospholipids, J Mol Biol 1965, 13, 238-252.
49. Schubert R. In: Müller R, Hildebrand G (Eds), Liposomes in drug formulations. Pharmazeu-tische Technologie Moderne Arzneiformen, pp. 219-237. WV GmbH, Stuttgart, 1998.
50. Ghyczy M. In: Müller R, Hildebrand G (Eds.), Drugs with phosphatidylcholine and liposomes: Development, assessment, perspectives, Pharmazeutische Technologie Moderne Arzneiformen, pp. 207-218. WV GmbH, Stuttgart, 1998.
51. Yamaouchi, et al.: Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes, Int J Pharm 1995, 113, 141-148.
52. Wright S, et al.: Antibody-directed liposomes as drug-delivery vehicles, Adv Drug Deliv Rev 1989, 3, 343-389.
53. Maruyama K, et al.: Characterization of in vivo immunoliposomes targeting to pulmonary endothelium, J Pharm Sci 1990, 74, 978-984.
54. Jurcic JG, et al.: Monoclonal antibody therapy of cancer. Cancer Chemother Biol Response Modif 1997, 17, 195-216.
55. Iakoubov, LZ, Torchilin VP: A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice, Oncol Res 1997, 9, 439-446.
56. Iakoubov L, et al.: Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells, Immunol Lett 1995, 47, 147-149.
57. Sunamoto J, et al.: Protein anchored and polysaccharide anchored liposomes as drug carriers, CRC Crit Rev Ther Drug Carrier Syst 1986, 2, 117-136.
58. Vias S: Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization, J Pharm Pharmacol Sci 2001, 4, 138-158.
59. Sunamoto J, et al.: Improved drug delivery to target specific organs using liposomes anchored with polysaccharides. In: Chiellini E, Giusti P (Eds.), Polymers in Medicine, pp. 157-168. Plenum Press, NY, 1984.
60. Akiyoshi K, et al.: Cell specificity of polysaccharide derivatives on liposomal surface, Chem Lett 1990, 473, 1990-1992.
61. Cleland JL, Langer R: Formulation and delivery of proteins and peptides: design and development strategies. In: Cleland JL, Langer R (Eds.), Protein Formulations and Drug Delivery. Washington, DC: ACS Symposium Series, pp. 1-21. American Chemical Society, 1994.
62. Bartus RT, Tracy MA, Emerich DF, Zale SE: Sustained delivery of proteins for novel therapeutic agents, Science 1998, 281, 1161-1162.
63. Langer R: Biomaterials in drug delivery and tissue engineering: one laboratory's experience, Accounts Chem Res 2000, 33, 94-101.
64. Benoit JP, Faisant N, Venier-Julienne MC, Menei P: Development of microspheres for neurological disorders: from basics to clinical applications, J Control Release 2000, 65, 285-296.
65. Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A, Cleland JL: Development of poly-(D,L-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis, J Control Release 2001, 69, 13-24.
66. Jeong B, Choi YK, Bae YH, Zentner G, Kim SW: New biodegradable polymers for injectable drug delivery systems, J Control Release 1999, 62, 109-114.
67. Jung T, Breitenbach A, Kissel T: Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-coglycolide) s facilitate the preparation of small negatively charged biodegradable nanospheres, J Control Release 2000, 67, 157-169.
68. Breitenbach A, Li YX, Kissel T: Branched biodegradable polyesters for parenteral drug delivery systems, J Control Release 2000, 64, 167-178.
69. Heller J, Barr J, Ng SY, Shen HR, Schwach-Abdellaoui K, Einmahl S, Rothen-Weinhold A, Gurny R: Poly(ortho esters)-their development and some recent applications, Eur J Pharm Biopharm 2000, 50, 121-128.
70. Maeda M, Tani S, Sano A, Fujioka K: Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs, J Control Release 1999, 62, 313-324.
71. Moriyama K, Ooya T, Yui N: Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation, J Control Release 1999, 59, 77-86.
72. Fessi H, Puisieux F, Devissaguet, JP, Ammouri, N, Benita S: Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int J Pharm 1989, 55, R1.
73. Tice TR, Gilley RM: Preparation of injectable controlled-release microcapsules by a solvent-evaporation process. J Control Release 1985, 2, 343-357.
74. Blanco D, Alonso MJ: Development and characterization of protein-loaded poly(lactide-coglycolide) nanospheres, Eur J Pharm Biopharm 1997, 43, 287-294.
75. Müller RH: Solid Lipid nanoparticles. In: Müller RH, Hildebrand GE (Eds.), Pharmazeutische Technologie: Moderne Arzneiformen, Chapter 21, WV GmbH Stuttgart, 1997.
76. Müller RH, Lucks JS: Arzneistoffträger aus festen Lipidteilchen (Feste Lipidnanosphären (SLN)), European Patent EP 0 605 497 B1, 1996.
77. Almeida AJ, Runge S, Müller RH: Peptideloaded solid lipid nanoparticles (SLN): influence of production parameters, Int J Pharm 1997, 149, 255-265.
78. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, Circulation 1999, 100, 1865-1871.
79. Johansen P, Men Y, Merkle HP, Gander B: Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000, 50, 129-146.
80. Okumu FW, Daugherty A, Sullivan SA, Tipton AJ, Cleland JL: Evaluation of SABER as a local delivery system for rhVEGF formulation design and in vitro assessment, Proc Int Symp Control Release Bioact Mater 2000, 27, 8034-8035.
81. Brodbeck KJ, Pushpala S, McHugh AJ: Sustained release of human growth hormone from PLGA solution depots, Pharm Res 1999, 16, 1825-1829.
82. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH: Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables, Eur J Pharm Biopharm 2000, 50, 257-262.
83. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL: Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys, J Biomed Mater Res 1999, 45, 231-239.
84. Ravivarapu HB, Moyer KL, Dunn RL: Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate, J Pharm Sci 2000, 89, 732-741.
85. Janes KA, Calvo P, Alonso MJ: Polysaccharide colloidal particles as delivery systems for macromolecules, Adv Drug Del Rev 2001, 83-97.
86. Dodane V, Vilivalam D: Pharmaceutical applications of chitosan, Pharm Sci Technol Today 1998, 1, 246-253.
87. Paul W, Sharma C: Chitosan, a drug carrier for the 21st century, STP Pharma Sci 2000, 10, 5-22.
88. Ohya Y, Shiratani M, Kobayashi H, Ouchi T: Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity, Pure Appl Chem 1994, A31, 629-642.
89. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ: Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers, J Appl Polym Sci 1997, 63, 125-132.
90. Calvo P, Bougaba A, Appel M, Fattal E, Alonso MJ, Couvreur P: Oligonucleotide-chitosan nanoparticles as new gene therapy vector, Proc World Meet APGI/APV 2 1998, 1111-1112.
91. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ: Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm Res 1999, 16, 1576-1581.
92. Bernkop-Schnürch A, Clausen AE: Biomembrane permeability of peptides: Strategies to improve their mucosal uptake, Mini Rev Med Chem 2002, 2, 295-305.
93. Bernkop-Schnürch A, Giovanelli R, Valenta C: Peroral administration of enzymes: Strategies to improve the galenic of dosage forms for trypsin and bromelain, Dev Ind Pharm 2000, 26, 115-121.
94. Aungst B: Intestinal permeation enhancers, J Pharm Sci 2000, 89, 429-442.
95. Bernkop-Schnürch A, Clausen AE, Guggi D: The use of auxiliary agents to improve the mucosal uptake of peptides, Med Chem Rev online 2004, 1, 1-10.
96. Drewe J, Fricker G, Voderscher J, Beglinger C: Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether, Br J Pharmacol 1993, 108, 298-303.
97. Morishita M, Morishita I, Takayama K, Yoshiharu M, Nagai T: Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and so-dium glycolate on intestinal absorption of insulin, Biol Pharm Bull 1993, 16, 68-72.
98. Richardson JL, Illum L, Thomas NW, Articles R: Vaginal absorption of insulin in the rat: effect of penetration enhancers on insulin uptake and mucosal histology, Pharm Res 1992, 9, 878-3883.
99. Sayani AP, Chun IK, Chien YW: Transmucosal delivery of leucine enkephalin: stabilization in rabbit enzyme extracts and enhancement of permeation through mucosae, J Pharm Sci 1993, 82, 1179-1185.
100. Hoogstraate AJ, Coos Verhoef J, Pijpers A, van Leengoed LA, Verheijden JH, Junginger HE, Bodde HE: In vivo buccal delivery of peptide drug buserelin with glycodesoxycholate as an absorption enhancer in pigs, Pharm Res 1996, 13, 1233-1237.
101. Aungst BJ, Rogers NJ: Site dependence of absorption-promoting actions of laureth-p, Na+salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal delivery of insulin, Pharm Res 1988, 5, 305-308.
102. Uchiyama T, Sugiyama T, Quan Y-S, Kotani A, Okada N, Fujita T, Muranishi S, Yamamoto A: Enhanced permeability of insulin across the rat intestinal membrane of various absorption enhancers: their intestinal mucosa toxicity and absorption enhancing mechanism of nlauryl-beta-D-maltopyranoside, J Pharm Pharmacol 1999, 51, 1241-1250.
103. Fasano A, Uzzau S: Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model, J Clin Invest 1997, 99, 1158-1164.
104. Hovgaard L, Brondsted H, Nielsen HM: Drug delivery studies in Caco-2 monolayers. II. Absorption enhancer effects of lysophosphatidylcholines, Int J Pharm 1995, 114, 141-149.
105. Gordon GG, Moses AC, Silver RD, Flier JS, Carey MC: Nasal absorption of insulin: Enhancement by hydrophobic bile salts, Proc Natl Acad Sci USA 1987, 82, 7419-7423.
106. Lee WA, Ennis RD, Longenecker JP, Bengtsson P: The bioavailability of intranasal calcitonin in healthy volunteers with and without a permeation enhancer, Pharm Res 1994, 11, 747-750.
107. Chiou GC, Shen ZF, Li BH: Effects of permeation enhancers BL-9 and Brij-78 on absorption of four peptide eyedrops in rabbits, Zhongguo Yao Li Xue Bao 1992, 13, 201.
108. Lueßen, HL, Rentel, CO, Kotze AF, Lehr CM, deBoer AG, Verhoef JC, Junginger HE: Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro, J Control Release 1997, 45, 15.
109. Artursson P, Lindmark T, Davis SS, Illum L: Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2), Pharm Res 1994, 11, 1358-1361.
110. Thanou M, Verhoef JC, Marbach P, Junginger HE: Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo, J Pharm Sci 2000, 89, 951.
111. Clausen AE, Bernkop-Schnürch, A: Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs, Eur J Pharm Biopharm 2001, 51, 25-32.
112. Bernkop-Schnürch A, Clausen AE, Hnatyszyn M: Thiolated polymers: synthesis and in vitro evaluation of polymer-cysteamine conjugates, Int J Pharm 2001, 226, 185-194.
113. Bernkop-Schnürch A, Schwarz V: Polymers with thiol groups: A new generation of mucoadhesive polymers? Pharm Res 1999, 16, 876-881.
114. Woodley JF: Peptidase enzymes of GIT; barriers to peptide delivery, but potential for controlled release, Crit Rev Ther Carrier Syst 1994, 11, 1496-1500.
115. Samanen J, Wilson G, Smith PL, Lee CP, Bondinell W, Ku T, Rhodes G, Nichols A: Chemical approaches to improve the oral bioavailability of peptidergic molecules, J Pharm Pharmacol 1996, 48, 119-135.
116. McMartin C, Hutchinson LEF, Hyde R, Peters GE: Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity, J Pharm Sci 1987, 76, 535-540.
117. Inagaki M, Sakakura Y, Itoh J, Ukai K, Miyosh Y: Macromolecular permeability of the tight junction of the human nasal mucosa, Rhinology 1985, 23, 213-221.
118. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L: Evaluation of the clear-ance characteristics of bioadhesive systems in humans, Int J Pharm 1999, 178, 55-65.
119. Lee VHL: Enzymatic barriers to peptide and protein absorption, CRC Crit Rev Ther Drug Carrier Syst 1988, 5, 69-97.
120. Illum L: Nasal drug delivery-possibilities, problems and solutions, J Control Release 2003, 87, 187-198.
121. Illum L, Watts P, Fisher AN, Jabbal-Gill I, Davis SS: Novel chitosan based delivery systems for nasal administration of a LHRHanalogue, STP Pharm 2000, 10, 89-94.
122. Patton JS: Pulmonary delivery of drugs for bone disorders, Adv Drug Deliv Rev 2000, 42, 239-248.
123. Shen Z, Zhang Q, Wei S, Nagai T: Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations, Int J Pharm 1999, 192, 115-121.
124. Gonda I: The ascent of pulmonary drug delivery, J Pharm Sci 2000, 89, 940-945.
125. Vanbever R, Ben-Jebria A, Mintzes JD, Langer R, Edwards DA: Sustained release of insulin from insoluble inhaled particles, Drug Dev Res 1999, 48, 178-185.
126. Kawashima Y, Yamamoto H, Takeuch H, Fujioka S, Hino T: Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect, J Control Release 1999, 62, 279-287.
127. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y, Ikada Y: Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption, J Pharm Pharmacol 2000, 52, 611-617.
128. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P: Factors and strategies for improving buccal absorption of peptides, Eur J Pharm Biopharm 2001, 51, 93-109.
129. Wearly LL: Recent progress in protein and peptide delivery by noninvasive routes, Crit Rev Ther Drug Carrier Syst 1991, 8, 331-394.
130. Lee VHL, Kashi SD, Patel RM, Hayakawa E, Inagaki K: Mucosal peptide and protein delivery: proteolytic activities in mucosal homogenates, Proc Int Symp Control Release Bioact Mater 1987, 14, 23-24.
131. Stratford RE, Lee VHL: Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery, Int J Pharm 1986, 30, 73-82.
132. Jacques Y, Buri P: Les systèmes thérapeutiques bioadhésifs à application buccale: aspects pharmacocinétiques, pharmacologiques et cliniques, chapter II. In: Muqueuse Buccale et Systèmes Therapeutiques Bioadhésifs, Medecine et Hygiène, Genève, 1998, 47-78.
133. Shojaei AH, Li X: Mechanisms of buccal mucoadhesion of novel copolymers of acrylic acid and polyethylene glycol monomethylether monomethacrylate, J Control Release 1997, 47, 151-161.
134. Li C, Bhatt PP, Johnston TP: Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch, Pharm Dev Technol 1997, 2, 265-274.
135. Wang W: Oral protein drug delivery, J Drug Target 1996, 4, 195-232.
136. Leone-Bay A, Santiago N, Achan D, Chaudhary K, DeMorin F, Falzarano L, et al.: N-acylated-amino acids as novel oral delivery agents for proteins, J Med Chem 1995, 38, 4263-4269.
137. Stoll BR, Leipold HR, Milstein S, Edwards DA: A mechanistic analysis of carriermediated oral delivery of protein therapeutics, J Control Release 2000, 64 217-228.
138. Leone-Bay A, Paton DR, Weidner JJ: The development of delivery agents that facilitate the oral absorption of macromolecular drugs, Med Res Rev 2000, 20, 169-186.
139. Reddy SM, Sinha VR, Reddy DS: Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs, Drugs Today 1999, 35, 537-580.
140. Spitael J, Kinget R: Solubility and dissolution rate of enteric polymers. Acta Pharm Technol 1979, 25, 163-168.
141. Chourasia MK, Jain SK: Polysaccharides for colon targeted drug delivery, Drug Deliv 2004, 11, 129-148.
142. Chickering DE, Mathiowitz E: Bioadhesive microspheres. I. A novel electrobalancebased method to study adhesive interactions between individual microspheres and intestinal mucosa, J Control Release 1995, 34, 251-262.
143. Chickering DE, Jacob JS, Mathiowitz E: Bioadhesive microspheres. 2. Characterisation and evaluation of bioadhesion involving hard, bioerodible polymers and soft-tissue. Reacting Polymers 1995, 25, 189-206.
144. Goldberg M, Gomez-Orellana I: Challenges for the oral delivery of macromolecules, Nature Rev Drug Discov 2003, 2, 289-295.
145. Lee HJ: Protein drug oral delivery: the recent progress, Arch Pharm 2002, 25, 572-584.
146. Hadgraft J, Guy RH: Transdermal drug delivery: developmental issues and research initiatives. New York: Marcel Dekker, 1989.
147. Potts RO, Guy RH: Predicting skin permeability, Pharm Res 1992, 9, 663-669.
148. Green PG, Hinz RS, Kim A, et al: Iontophoretic delivery of a series of tripeptides across the skin in vitro, Pharm Res 1991; 8, 1121-1127.
149. Menon GK, Bommannan DB, Elias PM: High-frequency sonophoresis: permeation pathways and structural basis for enhanced permeability. Skin Pharmacol 1994, 7, 130-139.
150. Cevc G, Schätzlein A, Blume G: Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Release 1995; 36, 3-16.
151. Cevc G, Blume G: New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes, Biochim Biophys Acta 2001, 1514, 191-205.
152. Cevc G: Transdermal drug delivery of insulin with ultradeformable carriers, Clin Pharmacokinet 2003, 34, 461-474.
153. Cevc G: Drug delivery across the skin, Exp Opin Invest Drugs 1997, 6, 1887-1937.
154. Kanikkannan N: Iontophoresis-based transdermal delivery systems, Biodrugs 2002, 16, 339-347.
155. Gothelf A, Mir LM, Gehl J: Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation, Cancer Treatment Rev 2003, 29, 371-387.
156. Turner NG, Ferry L, Price M, et al.: Iontophoresis of poly-L-lysines: the role of molecular weight? Pharm Res 1997; 14, 1322-1331.
157. Kost J: Ultrasound-assisted insulin delivery and noninvasive glucose sensing, Diabetes Tech Therapeutics 2002, 4, 489-497.
158. Graff MR, McClunahan MA: Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe, Clin Ther 1998, 20, 486-496.
159. Martano W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR: Transdermal delivery of insulin using microneedles in vivo. Pharm Res 2004, 21, 947-952.
160. McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, Prausnitz MR: Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies, Proc Natl Acad Sci USA 2003, 100, 13755-13760.
161. Mukerjee EV, Collins D, Isseroff RR, Smith RL: Microneedle array for transdermal biological fluid extraction and in situ analysis, Sensors and Actuators A: Physical, 2004, 114(2-3), 267-275.
162. Kompella UB, Lee VHL: Delivery systems for penetration enhancement of peptide and protein drugs: design considerations, Adv Drug Deliv Rev 2001, 46, 211-245.
163. Niu C-H, Chiu Y-Y: FDA Perspective on peptide formulation and stability issues, J Pharm Sci 1998, 87 (11), 1331-1334.